Abstract Body

Background: National estimates of antiretroviral treatment (ART) need and coverage, based on CD4 cell count thresholds, are generated by most countries using the Spectrum model. This uses model parameters for survival and CD4 progression that are derived from separate analyses. We developed a model which simultaneously estimates CD4 decline and survival in HIV-positive individuals by age, sex, and geographic region. We use the largest pooled dataset to date, collating data from 50 HIV seroconverter cohorts and collaborations in Africa, Europe, North America and Asia.

Methods: We used a hidden Markov model to describe survival and CD4 decline following seroconversion in the absence of ART. The model estimates forward-only transition rates through six transient states characterised by ranges of decreasing CD4 levels, towards two absorbing states, corresponding to ART initiation and death. We stabilised variability in CD4 counts using a log transformation. Natural short-term fluctuations along with measurement errors in CD4 cell counts were accounted for using a normal measurement error model. Covariates were included on the transition rates and survival probabilities were estimated for each subgroup.

Results: The 27,511 eligible individuals had a median follow-up time of 3.55 (IQR 1.71, 6.20) years, were predominantly male (74.1%) and had a median age at seroconversion of 29.1 (IQR 24.4, 35.4) years. Of these individuals, 23,031 had recorded CD4 counts pre-ART, 1943 died, and 14,519 initiated ART. Median (95% CI) survival for males aged 20 years at seroconversion was 11.6 (10.6-12.1), 11.3 (10.5-11.7) and 9.0 (8.7-9.4) years in Africa, Europe/North America and Asia, respectively. The mean time from seroconversion to CD4 counts <500 cells/mm3 for males in Africa aged 20 years was 3.02 years, conditional on starting above 500 cells/mm3. Transition rates and all-cause mortality rates progressively increase with increasing age (hazard ratio [HR] 1.02, 95% CI 1.02-1.03 for every five years of age for CD4 stages, HR 1.17, 95% CI 1.17-1.18 for mortality).

Conclusions: CD4 decline and mortality after HIV infection in the absence of ART was similar in African, European and North American cohorts, but significantly faster for all ages in Asian cohorts. Older age is associated with an increased hazard for progression. Joint estimation of these parameters reveals heterogeneities between regions and ages, which should be incorporated into future HIV models to accurately estimate ART need and coverage.